Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : BioCryst Pharmaceuticals
Deal Size : $264.0 million
Deal Type : Divestment
BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed
Details : Under the agreement, BioCryst sell will its European Orladeyo (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, business to Neopharmed Gentili.
Product Name : Orladeyo
Product Type : Other Small Molecule
Upfront Cash : $250.0 million
June 27, 2025
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : BioCryst Pharmaceuticals
Deal Size : $264.0 million
Deal Type : Divestment
Lead Product(s) : Mesoglycan
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Recipient : Societa Italiana di Chirurgia ColoRettale
Deal Size : Inapplicable
Deal Type : Inapplicable
Mesoglycan for Acute Hemorrhoidal Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Mesoglycan
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Recipient : Societa Italiana di Chirurgia ColoRettale
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesoglycan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Recipient : Quovadis Associazione
Deal Size : Inapplicable
Deal Type : Inapplicable
Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2018
Lead Product(s) : Mesoglycan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : Quovadis Associazione
Deal Size : Inapplicable
Deal Type : Inapplicable